Search research articles
Contact Us
Filters
Showing results (71-80 of 111) with videos related to
Page
of 12
Sort By:
Muscle & Nerve
|
June 9, 2025
Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment
Angela Genge, Gary L Pattee, Gen Sobue, et al.
Computerized Medical Imaging and Graphics : the Official Journal of the Computerized Medical Imaging Society
|
August 13, 2023
SF2Former: Amyotrophic lateral sclerosis identification from multi-center MRI data using spatial and frequency fusion transformer
Rafsanjany Kushol, Collin C Luk, Avyarthana Dey, et al.
Journal of Neuromuscular Diseases
|
April 19, 2021
A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method
Jeremy Slayter, Victoria Hodgkinson, Josh Lounsberry, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
March 7, 2022
Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches
Corey T McMillan, Joanne Wuu, Katya Rascovsky, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|
November 16, 2018
Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis
Victoria L Hodgkinson, Josh Lounsberry, Ario Mirian, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
April 3, 2015
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement
Zachary Macchi, Yunxia Wang, Dan Moore, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 27, 2021
Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices
Kristiana Salmon, Nancy Anoja, Ari Breiner, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
November 21, 2023
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
Baltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
March 17, 2026
ALS motor phenotypes: a revised 'OPM' classification
Thomas Meyer, Nicola Ticozzi, Markus Weber, et al.
The Lancet. Neurology
|
February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Vincent Meininger, Angela Genge, Leonard H van den Berg, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 111) with videos related to
Sort By:
Page
of 12
Muscle & Nerve
|
June 9, 2025
Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment
Angela Genge, Gary L Pattee, Gen Sobue, et al.
Computerized Medical Imaging and Graphics : the Official Journal of the Computerized Medical Imaging Society
|
August 13, 2023
SF2Former: Amyotrophic lateral sclerosis identification from multi-center MRI data using spatial and frequency fusion transformer
Rafsanjany Kushol, Collin C Luk, Avyarthana Dey, et al.
Journal of Neuromuscular Diseases
|
April 19, 2021
A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method
Jeremy Slayter, Victoria Hodgkinson, Josh Lounsberry, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
March 7, 2022
Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches
Corey T McMillan, Joanne Wuu, Katya Rascovsky, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|
November 16, 2018
Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis
Victoria L Hodgkinson, Josh Lounsberry, Ario Mirian, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
April 3, 2015
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement
Zachary Macchi, Yunxia Wang, Dan Moore, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 27, 2021
Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices
Kristiana Salmon, Nancy Anoja, Ari Breiner, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
November 21, 2023
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
Baltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
March 17, 2026
ALS motor phenotypes: a revised 'OPM' classification
Thomas Meyer, Nicola Ticozzi, Markus Weber, et al.
The Lancet. Neurology
|
February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Vincent Meininger, Angela Genge, Leonard H van den Berg, et al.
Page
of 12